Contact a Lawyer Now
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 16, 2021 to file lead plaintiff applications in a securities class action lawsuit against Annovis Bio, Inc. (NYSE: ANVS).
Annovis and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On July 28, 2021, post-market, the Company disclosed that interim clinical data from the Phase 2a trial of its lead compound, ANVS401 (Posiphen), failed to show statistically significant improvement compared to placebo in AD patients 25 days after treatment and, although patients showed cognitive improvements in certain areas, the results were not statistically significant.
On this news, shares of Annovis plummeted $65.94, or 60%, to close at $43.50 per share on July 29, 2021, on unusually heavy trading volume.
If you purchased securities of Annovis and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (firstname.lastname@example.org), or fill out the form on this page.
The case is Zhou v. Annovis Bio, Inc., No. 21-cv-03668.
Click here to read the first filed complaint.